Glecaprevir/pibrentasvir regulatory update

FDA granted breakthrough therapy designation for glecaprevir/pibrentasvir from AbbVie to treat chronic HCV genotype 1 infection in patients who failed prior therapy with direct-acting antivirals (DAAs...